Mr. Muhammad Tariq Khan (PhD Scholar RIU, Islamabad)
Mr. Tariq Khan has completed the M.Phil. Degree from Bahauddin Zakariya University, Multan, Pakistan, in 2014. He worked at different positions in Pharmaceutical marketing and teaching institutions. Mr. Tariq Khan has broad research interests in the areas of Medicinal Chemistry. During his studies, he remained President of Blood Donor Society, which shows his dedication to humanity and leadership qualities. He has showed a good academic record. He has vast experience in different research areas and extra-curricular activities. He is interested in pursuing a career in academics, seeking a challenging position to utilize his skills and abilities in the field of Education that offers a professional growth while being resourceful and innovative.
|PhD Scholar||Pharmaceutical Chemistry||Riphah International University, Islamabad||Since –|
|MPhil||Pharmaceutical Chemistry||Bahauddin Zakariya University, Multan||2014|
|Pharm.D||Pharmaceutical Sciences||University of Sargodha, Sargodha||2011|
TEACHING EXPERIENCE Lecturer Capital University of Science and Technology (CUST), Islamabad Since – October 2018 Assistant Professor Pakistan Margalla College of Pharmacy, Rawalpindi January 2018 – October 2018 Lecturer Mohi-ud-Din Islamic University, Mirpur September 2014 – January 2018 PROFESSIONAL EXPERIENCE Product Manager UniMark Pharmaceuticals Ltd. February 2013 – September 2014 Product Specialist 3A Pharmaceuticals Ltd. February 2012 – July 2012 Medical Sales Executive GlaxoSmithKline Pvt. Ltd. 2011 – 2012 MEMBERSHIP OF PROFESSIONAL BODIES Member Punjab Pharmacy Council, Lahore, Pakistan
RESEARCH AREAS / INTERESTS
- Medicinal Chemistry;
- Pharmaceutical Chemistry;
- Drug Designing and Virtual Screening.
JOURNAL PUBLICATIONS 1. A. M. Alvi, L. T. A. Kury, M. U. Ijaz, F. A. Shah, M. T. Khan, A. S. Sheikh, H. Nadeem, A. Khan, A. Zeb, S. Li, “Post-treatment of synthetic polyphenolic 1,3,4 oxadiazole compound A3, attenuated ischemic stroke-induced neuroinflammation and neurodegeneration.” Biomolecules, vol. 10, no. 1, pp. 816, 2020 2. S. Iqbal, F. A. Shah, K. Naeem, H. Nadeem, S. Sarwar, Z. Ashraf, M. Imran, T. Khan, T. Anwar, and S. Li, 2020. “Succinamide Derivatives Ameliorate Neuroinflammation and Oxidative Stress in Scopolamine-Induced Neurodegeneration.” Biomolecules, vol. 10, no. 3, pp. 443, 2020. 3. M. T. Khan, M. T. Razi, S. U. Jan, M. Mukhtiar, R. Gul, I. Ullah, A. Hussain, A. M. Hashmi, M. T. Ahmad, N. A. Shahwani, and I. Rabbani, “Synthesis characterization and antihypertensive activity of 2-Phenyl substituted benzimidazoles.” Pakistan Journal of Pharmaceutical Sciences, vol. 31, no.3, pp. 1067-1074, 2018. 4. M. Hanif, H. U. Khan, S. Afzal, M. T. Khan, K. Afzal, and N. Iqbal, “Sustained release ivabradine lipospheres from camauba wax/stearic acid blend: formulation, evaluation, and optimization by central composite design,” Latin American Journal of Pharmacy, vol. 36, no. 1, pp. 25-36, 2017. 5. H. Khan, A. Mahmood, S. Maheen, R. M. Sarfaraz, A. Youchi, A. Shameem, M. Akhtar, H. Ahsen, M. T. Khan, M. Khalil, and T. M. Rana, “Formulation and in vitro evaluation of novel antidiabetic orodispersible tablets using kyron-t134 and crosscaramellose sodium as superdisintegrants.” Latin American Journal of Pharmacy, vol. 33, no. 4, pp. 631-639, 2014. 6. M. T. Razi, I. Javed, M. Z. Choudary, M. T. Khan, and N. Mukhtar, “Effect of ketoprofen on lactic dehydrogenase from human platelets,” Advances in Clinical and Experimental Medicine, vol. 23, no. 3, pp. 377-380, 2013. 7. M.T. Khan, H. Nadeem, A.U. Khan, M. Abbas, M. Arif, N.S. Malik, Z. Malik and I. Javed, “Amino acid conjugates of 2‐mercaptobenzimidazole provide better anti‐inflammatory pharmacology and improved toxicity profile”, Drug Development Research, pp.1-16, 2020. https://doi.org/10.1002/ ddr.21728